Ranbaxy's FY 2007 profit up 68% $191M

Full-year 2007 profits at New Dehli, India-based drugmaker Ranbaxy Laboratories jumped 68% on the previous year to 7.9 billion rupees ($191.0 million), as earnings before interest, depreciation, tax and amortization reached $242.0 million, which reflects margin to sales of 15%. Excluding foreign exchange gains or losses on translation, the generics giant noted that EBIDTA margins were at 16.5% to sales, exceeding company guidance.

Emerging markets continue their strong growth momentum, comprising 54% of global sales, up from 49% in 2006, with 32% growth. The company's turnover reached $386.0 million, an increase of 2%. Base business growth in the USA was at 19%, excluding sales of first-to-file products. European operations saw record sales of $363.0 million, up 24%, with Romania, German, and the UK putting in a robust performances and France seeing a marked improvement over the previous year. In its domestic market, the firm says it continues to grow, maintaining its rank amongst the top two companies in the marketplace with a 5.04% share. Meanwhile its US branded business saw sales of $56.0 million, up 37%, led by its flagship dermatology product Sotret (isotretinoin), which achieved 51.5% market share.